denali therapeutics inc. (“denali”) is a biotechnology company focused on the discovery and development of therapies for patients with neurodegenerative diseases, including alzheimer’s disease, parkinson’s disease, als and others. denali was founded by scientists, industry experts and investors who share the vision that recent scientific insights into the genetic causes and biological processes underlying neurodegenerative disease, together with new translational medicine tools, offer an unprecedented opportunity to discover and develop effective medicines. denali is rigorously pursuing a science-driven approach to translational medicine and clinical development. founding investors include fidelity biosciences, arch venture partners, flagship ventures and the alaska permanent fund (represented by crestline investors).
Company profile
Ticker
DNLI
Exchange
Website
CEO
Ryan Watts
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Denali BBB Holding Limited • Denali Therapeutics CH GmbH ...
DNLI stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
18 Apr 24
DEFA14A
Additional proxy soliciting materials
18 Apr 24
DEF 14A
Definitive proxy
18 Apr 24
S-3ASR
Automatic shelf registration
22 Mar 24
D
$499.73 mm in equity / options, sold $499.73 mm, 11 investors
1 Mar 24
S-8
Registration of securities for employees
27 Feb 24
10-K
2023 FY
Annual report
27 Feb 24
8-K
Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
27 Feb 24
8-K
Denali Therapeutics Announces $500 million Private Placement Equity Financing
27 Feb 24
8-K
Regulation FD Disclosure
16 Feb 24
Latest ownership filings
4
VICKI L SATO
17 Apr 24
144
Notice of proposed sale of securities
15 Apr 24
4
Steve E. Krognes
2 Apr 24
144
Notice of proposed sale of securities
1 Apr 24
4
Ryan J. Watts
29 Mar 24
4
VICKI L SATO
19 Mar 24
4
VICKI L SATO
20 Feb 24
4
Steve E. Krognes
15 Feb 24
4
Ryan J. Watts
15 Feb 24
4
Carole Ho
15 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 149.59 mm | 149.59 mm | 149.59 mm | 149.59 mm | 149.59 mm | 149.59 mm |
Cash burn (monthly) | (no burn) | (no burn) | 37.93 mm | 14.12 mm | 29.12 mm | 27.67 mm |
Cash used (since last report) | n/a | n/a | 257.77 mm | 95.97 mm | 197.89 mm | 188.01 mm |
Cash remaining | n/a | n/a | -108.18 mm | 53.61 mm | -48.31 mm | -38.42 mm |
Runway (months of cash) | n/a | n/a | -2.9 | 3.8 | -1.7 | -1.4 |
Institutional ownership, Q3 2023
98.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 192 |
Opened positions | 29 |
Closed positions | 39 |
Increased positions | 73 |
Reduced positions | 56 |
13F shares | Current |
---|---|
Total value | 2.20 tn |
Total shares | 140.74 mm |
Total puts | 33.60 k |
Total calls | 77.60 k |
Total put/call ratio | 0.4 |
Largest owners | Shares | Value |
---|---|---|
Baillie Gifford & Co | 14.68 mm | $302.87 bn |
BIIB Biogen | 13.31 mm | $477.44 mm |
BLK Blackrock | 10.89 mm | $224.56 bn |
ARCH Venture Fund VIII | 10.67 mm | $893.61 mm |
Vanguard | 10.60 mm | $218.63 bn |
Wellington Management | 7.29 mm | $150.37 bn |
Temasek | 6.90 mm | $142.26 bn |
Douglas K Bratton | 6.86 mm | $0.00 |
Crestline Management | 5.96 mm | $122.97 bn |
STT State Street | 4.28 mm | $88.20 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Apr 24 | Sato Vicki L | Common Stock | Sell | Dispose S | No | Yes | 18.29 | 1,666 | 30.47 k | 118,043 |
1 Apr 24 | Krognes Steve E. | Common Stock | Sell | Dispose S | No | Yes | 20.5 | 92,500 | 1.90 mm | 47,341 |
29 Mar 24 | Watts Ryan J. | Common Stock | Gift | Dispose G | Yes | No | 0 | 40,000 | 0.00 | 2,202,604 |
15 Mar 24 | Sato Vicki L | Common Stock | Sell | Dispose S | No | Yes | 20.1 | 1,666 | 33.49 k | 119,709 |
13 Feb 24 | Krognes Steve E. | Common Stock | Sell | Dispose S | No | No | 17.29 | 2,750 | 47.55 k | 139,841 |
News
UBS Maintains Buy on Denali Therapeutics, Lowers Price Target to $32
9 Apr 24
Goldman Sachs Maintains Buy Rating for Denali Therapeutics: Here's What You Need To Know
29 Feb 24
Goldman Sachs Maintains Buy on Denali Therapeutics, Lowers Price Target to $50
29 Feb 24
4 Analysts Assess Denali Therapeutics: What You Need To Know
28 Feb 24
HC Wainwright & Co. Maintains Buy on Denali Therapeutics, Lowers Price Target to $95
28 Feb 24
Press releases
Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences
8 Apr 24
Flagship Pioneering Named to Fast Company's Annual List of the World's Most Innovative Companies of 2024
19 Mar 24
Denali Therapeutics Announces $500 million Private Placement Equity Financing
27 Feb 24